secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093947
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M
-------------------------------------------------------------------------

- Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.
- Cash and equivalents $38.5M as of June 30; expected to fund operations into Q4 2025.
- OpRegen Phase 1/2a data: mean BCVA gain +5.5 letters at 24 months in less advanced GA patients (n=10).
- OPC1 spinal cord injury study startup activities ongoing; hosted 2nd Annual SCI Investor Symposium.
- Services agreement with Genentech initiated for OpRegen development support, fully funded by Genentech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/0000950170-24-093947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/lctx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer